Citi Says AppLovin Is Positioned to Meet or Beat Q3 Guidance
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.
Already have an account? Sign in.
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.
The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.
The FDA has approved Pharming’s Joenja as the first U.S. treatment for children ages 4–11 with APDS who weigh at least 27 kg.